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Abstract
The manifestation of chronic back pain depends on structural, psychosocial, occupational and genetic influences. Heritability estimates
for back pain range from 30% to 45%. Genetic influences are caused by genes affecting intervertebral disc degeneration or the immune
response and genes involved in pain perception, signalling and psychological processing. This inter-individual variability which is partly
due to genetic differences would require an individualized pain management to prevent the transition from acute to chronic back pain
or improve the outcome. The genetic profile may help to define patients at high risk for chronic pain. We summarize genetic factors that
(i) impact on intervertebral disc stability, namely Collagen IX, COL9A3, COL11A1, COL11A2, COL1A1, aggrecan (AGAN), cartilage inter-
mediate layer protein, vitamin D receptor, metalloproteinsase-3 (MMP3), MMP9, and thrombospondin-2, (ii ) modify inflammation,
namely interleukin-1 (IL-1) locus genes and IL-6 and (iii ) and pain signalling namely guanine triphosphate (GTP) cyclohydrolase 1, 
catechol-O-methyltransferase,   opioid receptor (OPMR1), melanocortin 1 receptor (MC1R), transient receptor potential channel A1 and
fatty acid amide hydrolase and analgesic drug metabolism (cytochrome P450 [CYP]2D6, CYP2C9).
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Introduction
The manifestation of back pain is contributed by structural, psy-
chosocial and occupational influences [1]. Biochemical and
inflammatory factors contribute to the transition of acute towards
chronic pain and genetic factors may modulate any of these fac-
tors. Research has been mainly focused on genes that determine
bone and cartilage structure and are accompanied by morphological
signs in magnetic resonance imaging (MRI). Genetic associations
were found for disc height narrowing and different definitions of
back pain, such as duration of the worst back pain episode and
hospitalization for back problems [2]. The heritability estimates for
these back pain variables ranged from 30% to 45% [2].
However, only a minority of the genetic influences was caused
by genes affecting disc degeneration suggesting that genes
involved in pain perception, signalling and psychological process-
ing [3] and genetic variants of immune genes [4] contribute to the
proportion of heritability of chronic back pain. Individuals vary
widely in their sensation and experience of pain [5, 6] and the risk
of developing chronic back pain. This inter-individual variability
which is partly due to genetic differences in pain signalling mole-
cules would require an individualized pain management which is
hampered by the still limited pharmacological treatment options.
The genetic variability in the pharmacodynamic and kinetic effects
of analgesic agents further contribute to the variable risk of devel-
oping chronic back pain because it may interfere with treatment
strategies or cause unexpected drug toxicity. In this review, we will
summarize genetic factors that specifically modify intervertebral1606
disc stability, pain signalling and analgesic drug metabolism that may
independently impact on the risk of developing chronic back pain.
Genetic polymorphisms associated
with intervertebral disc disease (IDD)
IDD is characterized by disc degeneration and herniation and is
often associated with low back pain and lumbar radicular pain due
to nerve root compression or inflammation. Sensory neurons and
sensory fibres from multiple spinal cord levels innervate interver-
tebral discs [7] explaining the often widespread back pain. An
increased risk of low back pain was found in relation to all signs
of disc degeneration [8, 9]. However, morphological signs alone
are of limited predictive value for chronic back pain. Genetic vari-
ants of the genes encoding molecules of extracellular matrix pro-
teins and other structural proteins have been associated with MRI
correlates of degenerative disc disease [10–15] and with chronic
low back pain with lumbar radicular pain [16–18]. Collagen is a
major component of the extracellular matrix and regulates carti-
lage fibril formation within intervertebral discs. It is a het-
erotrimeric protein consisting of three  -chains. Polymorphisms
in the gene coding for the  2 and   3 chains of collagen IX,
COL9A2 and  COL9A3 were associated with alterations in the
mechanical properties of human intervertebral discs and con-
tribute to the susceptibility for lumbar disc herniation and back
pain [10, 16, 17, 19–21]. Several IDD associated COL9A2 alleles
were identified. The so called Trp2 allele representing a Gln326Trp
amino acid exchange in the  2 chain was associated with prema-
ture disc degeneration and back pain in Finnish, Japanese and
Chinese populations [11, 16, 17, 19]. The Trp2 variant however,
was not detected in Germans [20] or Greek [18] but a high relapse
rate of lumbar disc disease after surgery was detected in carriers
of the Gln326Arg variant of collagen IX (COL9A2) [20]. The
COL9A3 variant associated with lumbar disc disease is also char-
acterized by an amino acid exchange from arginine to tryptophan,
the so-called Trp3 variant [10, 13, 14], suggesting that the variant
tryptophan as the most hydrophobic amino acid in either the  2 or
 3 chain of collagen IX disrupts the collagen IX triple helix or the
assembly with type XI and II collagens. In addition to the Trp2
allele, a splice site mutation of COL9A2 was detected in a patient
with lumbar disc stenosis leading to the generation of a truncated
protein [22]. Presumably the variants reduce the stability of carti-
lage collagen and thereby increase the risk of disintegration of the
extracellular matrix resulting in disc degeneration and herniation.
However, the exact functional consequences are still unknown.
Type X1 collagen is expressed in the annulus fibrosus and
nucleus pulposus. It is a minor component of human cartilage but
important for the formation of cartilage collagen. It is composed
of three  -chains,  1(XI),  2(XI) and  3(II), which are encoded by
COL11A1, COL11A2 and COL2A1, respectively. The three chains
fold into triple-helical heterotrimers to form procollagen, which is
secreted into the extracellular matrix, where it participates in fibril
formation with the other cartilage-specific collagens, type II and IX
collagens. Type XI collagen regulates the diameter of cartilage col-
lagen fibrils by limiting further apposition. Genetic variants in
COL11A1 were associated with an increased risk of lumbar disc
herniation in a Japanese cohort [23]. A single nucleotide polymor-
phism (c.4603C T) in the coding region of COL11A1 showed the
strongest association with disc herniation. The transcript of the
disease-associated T allele had reduced stability and the expres-
sion level was inversely correlated with the severity of disc degen-
eration [23]. In a Finnish population, carriers of the A allele of a
deletion splice site variant of COL11A2 (IVS6-4A/- or A/T) encod-
ing the  2(XI) chain had a lower risk for degenerative spinal steno-
sis with radicular pain than carriers of the T allele (T/- or T/T) [22].
Exon 6 and exon 8 were skipped in the presence of the T allele [22]
but functional consequences have not been analysed.
Carriers of the Sp1 variant of the  1 chain of type one collagen
(COLI1A1) were at risk of developing lumbar disc degeneration
[24] and have bone mineral density with osteoporotic bone frac-
tures particularly in postmenopausal women [24–28]. The Sp1
variant is a promoter polymorphism ( 1997 G/T) of COL1A1 that
interferes with the binding of the transcription factor Sp1. As a
result, COL1A1 expression is reduced in carriers of this variant
[29, 30]. This polymorphism was most frequently linked with
reductions of bone mineral density and osteoporosis [24, 29–32]
that represents a major cause of chronic low back pain [33].
Polymorphisms of various other genes such as transforming
growth factor-  (TGF- ) [34, 35], oestrogen receptor [36], the
vitamin D receptor [37, 38] and the low density lipoprotein genes
LRP5 and LRP6 [39, 40] contribute to the pathogenesis of osteo-
porosis and may therefore also contribute to the development of
back pain. Polymorphisms affecting bone mineral density have
been summarized in, e.g. [41, 42].
IDD was also associated with ‘variable number of tandem
repeat’ (VNTR) polymorphisms in the coding region of the human
aggrecan gene (AGAN) [43]. Thirteen different alleles have been
identified, with repeat numbers ranging from 13 to 33. This poly-
morphism is apparently restricted to human beings, of several
species examined. The polymorphism results in individuals with
differing length aggrecan core proteins, bearing different numbers
of potential attachment sites for chondroitin sulphate. Magnetic
resonance imaging (MRI) in healthy volunteers revealed the asso-
ciation of ACAN polymorphisms with MRI signs of IDD [43]. A
study in young Japanese women who presented to the
orthopaedic department for low back pain MRI scans revealed that
multilevel and severe disc degeneration was present in the
patients with shorter VNTR length of the aggrecan gene whereas
 25 repeats had protective effects [44]. The core aggrecan pro-
tein accounts for the tight collagen fibril network of the discs and
short variants may affect the resistance to compressive loads pre-
disposing to disc degeneration at an early age [44].
Variants of the gene coding for the cartilage intermediate layer
protein (CILP) [12, 45] were recently reported to affect the extra-
cellular matrix of joint cartilage [46]. In a case–control study a
functional single nucleotide polymorphism (SNP) in exon 8 of
CILP (T1184C) was shown to be associated with intervertebral
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disc degeneration [45]. CILP was expressed abundantly in inter-
vertebral discs, and its expression increased during progression
of disc degeneration. CILP colocalized with TGF- 1 in clustering
chondrocytes and directly inhibited both the TGF- 1 mediated
induction of cartilage matrix genes and the inhibition of metallo-
proteinase transcription. The aberrantly increased inhibitory
effects of CILP attributed to the susceptible allele probably perturb
the balance of TGF-  control over chondrocyte metabolism and
intervertebral disc tissue maintenance, leading to an increased
susceptibility to lumbar disc disease because intervertebral disc
cells respond inadequately to injury and mechanical stress.
A single adenine insertion/deletion polymorphism (6A/5A) in
the metalloproteinsase-3 (MMP3 11716A 5A) promoter region
was associated with modic changes in endplates of lumbar verte-
bral bodies in MRI scans in Finnish male workers, particularly if
carriers of the MMP3 variant had additional polymorphisms in
interleukin-1 (IL-1) locus genes [47]. In a cohort of Japanese mid-
dle-aged women MMP3 genotypes with at least one 5-adenine
allele (5A5A and 5A6A) were associated with degenerative
changes in lumbar intervertebral discs [48]. The mechanism of
this association has been suggested by in vitro studies of pro-
moter activity. The 5A promoter had higher activity compared to
that of the 6A allele in both cultured fibroblasts and vascular
smooth muscle cells. Thus, persons with the ‘slow-promoter’
6A6A genotype would be predicted to have lower expression and
activity of MMP3. However, the higher transcriptional activity
associated with the 5A allele required an inflammatory stimulus
not occurring during basal conditions suggesting that additional
predisposing factors will enhance the impact of this variant. As
MMP-3 was recently found to play a major role in the inflamma-
tory response in the spinal cord following peripheral nerve injury
and to contribute to the development of neuropathic pain [49] this
variant may additionally increase the susceptibility to radicular sci-
atic pain in addition to low back pain.
In addition to MMP3, a single missense polymorphism in met-
allaoproteinase-9 (MMP9) causing a change from glutamine to
arginine at position 279 in MMP-9 protein was strongly associated
with lumbar disc herniation in two independent Japanese cohorts
[50]. This polymorphism showed a combinatorial effect with an
intronic variant of the thrombospondin-2 gene (THBS2:
IVS10–8C T) that itself was also significantly associated with
lumbar disc herniation. This THBS2-SNP is located in a polypyrim-
idine tract upstream of the 3  splice site of intron 10 and exerts
allelic differences on exon 11 skipping rates in vivo, with increased
skipping in the variant allele. Skipping of exon 11 results in
decreased thrombospondin-2 interaction with MMP2 and MMP9
[50] probably increasing the activity of these MMPs. MMP9 also
plays a major role in the manifestation of neuropathic pain follow-
ing nerve injury [49] suggesting that variants in thrombospondin
and MMP9 may also increase the risk of chronic pain in carriers of
these variants.
Carriers of some variants of the vitamin D receptor gene may
also be at a higher risk for IDD and osteoporosis. A common C to
T polymorphism in exon 2 of the vitamin D receptor gene (VDR)
introduces a new translation start site and in a protein that differs
in length by three amino acids and was identified with the restric-
tion enzyme FokI. Some studies suggest that the longer variant is
correlated with lower bone mineral density in some populations
[37] and lumbar disc degeneration [15, 51, 52]. A further ‘restric-
tion site’ variant was identified with the enzyme Taq1 [53]. It was
also associated with lumbar disc disease [53].
As extracellular matrix protein polymorphisms increase the
susceptibility to degeneration of discs and/or bone of the spine
they may increase the risk for chronic back pain. However, these
genetic variants do not directly affect pain sensation or signalling
or adaptations of peripheral and central pain circuits. A prospec-
tive trial in a cohort of 100 patients with structural and psychoso-
cial risk factors revealed that the development of serious disability
due to low back pain was strongly predicted by baseline psy-
chosocial variables but only weakly by baseline structural MRI
variables suggesting that the degree of structural changes does
not allow to predict the intensity and frequency of low back pain
[54]. The risk conferred by genetic variants of extracellular matrix
(ECM) genes is further contributed by the risk conferred by inflam-
matory and pain signalling genes discussed below.
Polymorphisms in pro-inflammatory
genes
Inflammation plays a major role in the development of IDD [55].
The extent and resolution of inflammation is modified by genetic
variants in cytokine genes. Particularly, polymorphisms in the IL-1
gene locus were suspected to contribute to the development of
low back pain because single nucleotide variants of IL-1  (IL1A),
IL-1  (IL1B) and IL-1 receptor antagonist (IL1RN) modify bone
mineral density [56] and promote IDD [14, 57]. Herniated discs
produce several inflammatory mediators such as IL-1, IL-6 and
tumour necrosis factor-  (TNF- ) which maintain the inflamma-
tory process and sensitize nociceptors that innervate the affected
discs or the surrounding tissue [58, 59]. In a Finnish study in mid-
dle-aged men carriers of the IL-1 receptor antagonist G1821 A
allele had an increased risk of low back pain [4]. In addition, car-
riers of this allele in combination with the IL1A C889 T allele or
IL1B C3954 T variant had a higher risk of developing low back
pain than non-carriers, and reported more days with pain and
higher intensities of low back pain [4]. The results suggest that IL-1
gene locus polymorphisms promote or prolong low back pain,
supported by a recent study that evaluated MRI changes in end-
plates of lumbar vertebral bodies and their association with chronic
low back and sciatic pain [60]. Vertebral endplate changes in MRI,
so called modic changes, were interpreted as a morphological
marker for inflammatory degenerative IDD. Affected sites showed
an enhanced number of sensory nerve fibres and TNF-expressing
immune cells explaining the associated back pain syndrome [61].
Out of various pro-inflammatory genes combined polymorphisms in
IL1A and the 5-adenine promoter polymorphism of metallopro-
teinase-3 were associated with such modic changes [47]. In addition
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to IL1, polymorphisms in the IL6 gene were associated with IDD
in patients with discogenic lumbar radicular pain [62]. The IL6
promoter variations G-597A and G-174C and the T15A polymor-
phism in exon 5 were increased in Finnish patients with IDD, compared
with non-affected controls [62]. Several other pro-inflammatory
gene polymorphisms including variants of IL2, TNF , IL4 and inter-
feron-  were evaluated in this study but had almost identical allele
frequencies in low back pain patients and controls [62]. The IL6
promoter polymorphisms increase the transcription and secretion
of IL6. This will probably enhance the inflammatory response or
interfere with the resolution of inflammation.
Polymorphisms in the PTGS2 gene coding for cyclooxygenase
2 may modulate the development of inflammation as well as the
response to treatment with inhibitors of cyclooxygenases. This
has been proposed for the PTGS -765G C SNP, which was
reported to be associated with a more than twofold decrease in
COX-2 expression [63]. By altering a putative Sp1 binding site
[64], the PTGS2 gene variant decreased the promoter activity by
30% [65] and resulted in a net decrease in COX-2 function, quan-
tified by prostaglandin E2 production from peripheral blood
monocytes after stimulation with bacterial LPS [63]. This poly-
morphism was found to cause a failure of rofecoxib analgesia in
carriers of the -765C variant allele [66]. However, neither the 
-765G C associated lower COX-2 expression nor reduced effect
of COX-2 inhibitors were reproduced in a subsequent study in
healthy volunteers having received celecoxib [67].
Polymorphisms associated with subtle
modulations of pain sensitivity
MRI signs of bone and cartilage structure are weakly predictive for
chronic back pain suggesting that genetic variants in genes mod-
ifying pain sensation and signalling also contribute to the relative
high heritability estimates for chronic back pain. Only recently it
has been increasingly recognized that some frequent genetic poly-
morphisms are associated with modulations of pain sensitivity or
the development of hyperalgesia. These frequent polymorphisms
are not the cause of serious diseases but may change the risk for
chronic pain including chronic back pain. Associations between
candidate genes and chronic back pain and lumbar root pain were
evaluated in patients following lumbar disc surgery to remove her-
niated discs [68]. The patients suffered from serious long lasting
back and sciatic pain before surgery. In the first 2 years after surgery
pain scores for frequency and intensity at rest and during walking
were recorded every 3 months. The statistical analysis revealed that
patients with a defined set of single nucleotide polymorphisms in
the gene of the GTP cyclohydrolase 1 (GCH1) had consistently
less pain than non-carriers and a significantly better outcome after
surgery [68]. The polymorphisms in GCH1 that were associated with
reduced pain constitute a certain haplotype, referred to as ‘pain-
protective’ haplotype of GCH1, with a frequency of about 16% in the
Caucasian population. The GTP cyclohydrolase is the rate-limiting
enzyme in the synthesis of the enzyme cofactor, tetrahydro-
biopterin which is essential for the production of biogenic amines,
namely noradrenaline, dopamine and serotonin [69] and the synthe-
sis of nitric oxide [70]. It has been confirmed in further studies
that the ‘pain-protective’ haplotype is associated with a reduction of
the sensitivity to mechanical and heat stimulation and particularly the
development of inflammatory hyperalgesia [71]. Functionally, this
haplotype prevents the up-regulation of GCH1 and overproduction of
tetrahydrobiopterin that normally occurs upon pro-inflammatory
stimulation or peripheral nerve injury. Subsequently, the overpro-
duction of the downstream products, particularly nitric oxide, is
also prevented [68]. Nitric oxide has long been considered as a pain
mediator because it contributes to the manifestation of neuronal
hyperexcitability upon ongoing nociceptive stimulation [72, 73].
Other genetic polymorphisms have been associated with
reduced pain sensitivity [74] but most studies did not specifically
address chronic back pain. However, it appears reasonable to
hypothesize that polymorphisms that modulate other types of
chronic pain may also impact on the liability of developing chronic
back pain. Such pain-modulating gene variants were found for cat-
echol-O-methyltransferase (COMT ), transient receptor potential
channel A1 (TRPA1), melanocortin-1 receptor (MC1R), fatty acid
amide hydrolase (FAAH) and the  -opioid receptor (OPRM1).
COMT modulates specific aspects of human pain perception and
the risk for developing complex pain conditions including
migraine [75]. COMT metabolizes catecholamines and modifies
thereby the transmission of dopaminergic, adrenergic and nora-
drenergic pathways in the brain. Noradrenaline and serotonin are
mediators in inhibitory pain pathways originating in the brainstem
[76, 77] but also neurotransmitters in excitatory tracts and periph-
eral nociceptive neurons [78, 79]. A single nucleotide exchange in
the coding region of COMT leads to an amino acid substitution of
valine to methionine at position 158 (V158M), with impaired
translation of COMT mRNA, reduction of its enzyme activity and
reduced thermostability [75]. The V158M genotype was primarily
associated with the rate of temporal summation of heat pain [75].
Other SNPs of COMT exert a greater influence on baseline noci-
ceptive sensitivity and are inversely correlated with enzyme activ-
ity and the risk of developing myogenous temporomandibular
joint disorder (TMD) [80]. TMD is a common musculoskeletal pain
condition with a prevalence of about 10% and 3:1 female to male
ratio and is often associated with chronic back pain [81, 82].
Genetic factors are likely to contribute to the development of TMD
such as COMT, MC1R and OPRM1 [81, 82]. Interestingly, patients
carrying the V158M variant of COMT show an up-regulation of opioid
receptor expression [83]. This may be due to a compensatory
mechanism. It was proposed that the V158M polymorphism indi-
rectly regulates  -opioid receptor function [84] because carriers
of this variant showed increased sensitivity to analgesic effects of
morphine [85, 86] presumably because of the receptor up-regula-
tion. However, the exact link between COMT and opioid receptors
is still elusive.
Variants of the MC1R gene were reported to reduce pain sen-
sitivity [87] although a reproduction of this single finding, which
paralleled a similar finding in mice [87], was not reproduced in
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another human cohort [88]. Nevertheless, in volunteers with a red
hair, fair skin phenotype, which is the visible phenotype associated
with non-function variants in the MC1R gene, the analgesic effi-
cacy of  -opioid agonists, namely of the active morphine metabo-
lite, morphine-6-glucuronide, was increased in men and women
as well as in a respective mouse model as compared to carriers of
functional MC1R [87]. In contrast to  -opioid agonists,  -opioid
agonists, namely pentazocine, showed a sex-specific increased
analgesic activity in female carriers of non-functional MC1R but
not in males [89].
These studies verify that pain modulation in the two sexes
involves neurochemically distinct substrates. Interestingly, female
but not male carriers of a genetic variant of the cold receptor,
TRPA1 had increased sensitivity to cold-induced pain compared to
carriers of the wild-type allele [90]. TRPA1 is mainly activated by
noxious cold, chemical and endogenous irritants such as formalin
[91–93], bradykinin [94] and 4-hydroxynonenal [95]. It is also a
sensor for oxidative stress [96]. The genetic variant TRPA1 I585V
leads to an amino acid substitution from isoleucin to valin. The
functional consequence is unknown.
The sensitivity to pain and to opioid analgesia and side effects
is known to be modulated by variants in opioid receptors [97]. The
 -opioid receptor, encoded by the OPRM1 gene (OPRM1), is the
primary site of action of endogenous and of the most potent
exogenous common clinical opioid analgesics such as morphine,
fentanyl or methadone. A large number of polymorphisms have
been identified in the promoter region, in exons and introns of
OPRM1 [97, 98]. So far, most information has been accumulated
about the OPRM1 118A G SNP in exon 1 leading to an amino
acid substitution from asparagine to aspartate at position 40 of the
protein thereby deleting a putative extracellular glycosylation site.
This SNP is highly prevalent in the population with an allele fre-
quency of approximately 16% in Caucasians. At the molecular
level, it is thought to either decrease  -opioid receptor expression
[99] or, in a brain-region specific manner, agonist-stimulated
receptor signalling [100]. With respect to pain sensitivity, carriers of
this variant displayed higher pain thresholds [101] or lower cortical
responses to experimental pain stimuli [102]. This fits to neither of
the above-mentioned molecular mechanisms and is best explained
with an earlier molecular finding of increased binding affinity of 
 -endorphin at the variant  -opioid receptors [103], which, how-
ever, had not been reproduced [104, 105]. With respect to pain
treatment with exogenous opioids, the 118A G SNP significantly
reduced the potency of morphine-6-glucuronide [106, 107], mor-
phine [107] or levomethadone [108] in experimental studies in
healthy volunteers that evaluated pupil constrictory effects of the
opioids [106]. The OPRM1 118A G polymorphism reduced both
analgesic [74, 109] and respiratory depressive [109] effects of
alfentanil suggesting that the efficacy of various  -opioid receptor
agonists is affected by this variant. Moreover, two to four times
greater alfentanil requirements to achieve the same degree of anal-
gesia in homozygous carriers as compared to wild-type patients
was accompanied by 10–12 times greater dose requirements to
achieve the same degree of respiratory depression suggesting that
the OPRM1 118G variant somewhat protects against opioid induced
side effects [109], as previously already proposed for morphine-6-
glucuronide [110]. However, this might not be the case in heterozy-
gous carriers, in whom in two independent studies an increased
therapeutic range, analgesia versus respiratory depression, was
not observed [109, 111]. In the clinical setting, carriers of the
OPRM1 118A G polymorphism required significantly higher
doses of morphine in the early post-operative period following
knee surgery [112], abdominal hysterectomy [113] or other major
abdominal surgical interventions [114]. Cancer patients homozy-
gous for the 118 G allele also needed higher morphine doses to
achieve pain control [115], further modulated when these patients
had the wild-type COMT Val/Val genotype [86] or the wild-type
ABCB1 (P-glycoprotein) 3435C allele of the 3435C T SNP of this
transporter gene [116]. Thus, except for a single opposite report
[117] the OPRM1 118A G polymorphism appears to be well estab-
lished as a functional variant decreasing the effects of exogenous
opioids and possibly also moderately decreasing pain sensitivity.
A single experimental pain study reported a weak association
between heat and cold pain sensitivity and genetic variants of the
 -opioid receptor gene (OPRD1) in male but not female healthy
individuals [118]. However, mostly  -opioid receptor gene poly-
morphisms were associated with substance dependence [119] or
psychiatric disorders [120].
Endogenous cannabinoids (CBs), cannabis and its congeners
reduce pain and modify emotional components of pain through
agonistic action at peripheral and central CB-1 receptors [121,
122]. CBs additionally modify the immune response through CB-2
receptors. The immune modulation by CBs ameliorates inflamma-
tory processes including neuro-immune responses that contribute
to the manifestation and chronicity of neuropathic pain [123, 124].
Tetrahydrocannabinol, one of the constituents of marihuana has
the potential to reduce serious neuropathic pain in patients with
multiple sclerosis or other neuropathic pain syndromes [125].
However, polymorphisms in the CB-1 gene CNR1 have not been
associated with specific pain phenotypes, but were found to be
associated with obesity [126, 127], schizophrenia or efficacy of
neuroleptic treatment [128, 129] and drug and alcohol dependence
[130–132]. Polymorphisms in the CB-2 gene CNR2 play a role in
osteoporosis [133] and thereby possibly chronic back pain that is
often caused by osteoporosis of the spine with and without vertebral
fractures. Genetic variances in CNR2 might also modulate the sus-
ceptibility to autoimmune disorders [134]. The endocannabinoid
anandamide is rapidly re-uptaken through a CB transporter and
then metabolized by FAAH [135]. Inhibitors of FAAH prolong the
half-life of anandamide and other endocannabinoids and potently
reduce pain in rodent models [136, 137]. Polymorphisms in the
FAAH gene [138] cause an amino acid exchange from proline to
threonine at position 129 and result in decreased FAAH enzyme
catalytic activity [90]. This P129T mutation was associated with
slightly reduced sensitivity to cold pain in experimental settings in
healthy volunteers [90]. The potential modulation of the suscepti-
bility to chronic back pain has not been addressed. However, con-
sidering the functions of endocannabinoids on bone formation
and density and pain signalling [139, 140] it is likely that alterations
in their metabolism affect the susceptibility to chronic back pain.
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Polymorphisms contributing to chronic
widespread musculoskeletal pain
Chronic back pain is often associated with widespread pain in
complex musculoskeletal pain syndromes such as fibromyalgia
[141], TMD [142] and chronic fatigue syndrome [143].
Fibromyalgia is a generalized widespread chronic pain disorder
characterized by diffuse muscle pain throughout the body, most
often including chronic back and neck pain, muscle weakness,
fatigue, increased negative mood, sleep disturbance [141] and
comorbidity with anxiety and depression [144]. Chronic wide-
spread pain is common in the general population. The precise role
of genetic factors in the etiopathology is still unclear but polymor-
phisms in genes of the serotoninergic and catecholaminergic sys-
tems have been associated with an increased risk of fibromyalgia
and chronic fatigue syndrome. Polymorphisms in the monoamine
oxidase A (MAOA) which is one of the enzymes metabolizing sero-
tonin were reported to affect the rate of serotonin degradation and
may therefore impact on the risk of psychopathological symptoms
which are associated with fibromyalgia, other chronic widespread
pain syndromes and chronic back pain [145]. COMT polymor-
phisms may further contribute to the pathogenesis because
approximately 74% of fibromyalgia patients had low or intermedi-
ate COMT activity resulting in low catecholamine degradation
[146, 147] and Spanish fibromyalgia patients carrying a haploype
of COMT associated with high pain intensity (rs6269, rs4818 and
rs4680) had a higher risk for fibromyalgia and showed higher pain
intensities [148].
Polyarthropathic diseases such as ankylosing spondylitis,
rheumatoid arthritis, psoriatic arthritis or systemic lupus erythe-
matosus cause inflammatory back pain due to arthritis of the small
intervertebral or sacroiliacal joints and myositis. Polymorphisms
in the major histocompatibility complex molecules contribute to
the development of these diseases [149, 150]. However, several
other immune genes such as immunoglobulin receptors, TNF
receptor, transcription factors such as Stat4, various cytokines
and chemokines were shown to be associated with the risk of
developing these chronic inflammatory autoimmune diseases and
to modify the response to pharmacologic treatments with, e.g.
anti-TNF monoclonal antibodies or immunosuppressive agents.
Genetic susceptibility to autoimmune disorders have been sum-
marized in, e.g. [151–153].
Polymorphisms causing complex 
syndromes with a loss of pain 
perception
Several hereditary maladies with complete loss of pain sensitivity
have been genetically defined. Although the molecular mecha-
nisms differ among them, all syndromes are characterized by an
interruption of transmission or processing at key points of the
nociceptive system (for full details, see the ‘Online Mendelian
Inheritance in Man’ database: http://www.ncbi.nlm.nih.gov/sites/
entrez?db    omim) [74]. This includes (i) the channelopathy
associated insensitivity to pain, which is based on loss-of-function
mutations of the  -subunit of the voltage-gated sodium channel,
Na(v)1.7 [154, 155], (ii) the hereditary sensory and autonomic
neuropathy type I (HSAN-I), caused by mutations in the serine
palmitoyltransferase, long chain base subunit 1 gene [156–158],
(iii) the HSAN-II, based on mutations in the hereditary sensory
neuropathy, type II  [159, 160]; [161, 162], (iv) the HSAN-III due
to mutations in the inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase complex-associated protein gene
[163–165], (v) the HSAN-IV, also called congenital insensitivity to
pain with anhidrosis and based on mutations in the neurotrophic
tyrosine kinase, receptor, type 1 gene [166, 167] and (vi) the
HSAN-V caused by mutations in the nerve growth factor,  
polypeptide gene [168]. All these syndromes are very rare, affect-
ing a few families. Therefore, their specific association with back
pain has not been shown but it is reasonable to assume that
patients with these syndromes will not develop back pain.
Polymorphisms modulating 
the metabolism of analgesics
Early effective and safe pain therapy may help to prevent the tran-
sition to chronic pain [169] and drug-related secondary problems.
Polymorphisms in drug metabolizing enzymes may therefore be
important for the long-term outcome of back problems. The
cytochrome P450 (CYP) isoenzyme 2D6 metabolizes some opioid
analgesics, most importantly codeine and tramadol, but also
amitriptyline that is often used as a co-analgesic in patients with
neuropathic pain and might have some limited usefulness in lum-
bar root pain [170, 171]. Codeine ineffectiveness is partly caused
by the lack of formation of its active metabolite morphine, which
has a 200-times higher affinity and intrinsic activity at  -opioid
receptors than codeine itself [172, 173] and is therefore consid-
ered the active principle of codeine despite some evidence that
codeine or codeine-6-glucuronide contribute to the pharmacody-
namic effects [174–178]. In approximately 7% of the Caucasian
population, the CYP2D6 enzyme catabolizing codeine O-demethy-
lation to morphine [179] is known to be inactive for genetic rea-
sons [180], with differences in other ethnicities [181], and in these
individuals codeine fails to produce relevant clinical analgesia
[182, 183]. On the other hand, also in approximately 7% of the
Caucasian population, CYP2D6 is extremely active [181, 184]
leading to very high morphine formation from codeine. This chal-
lenges the safety of codeine therapy as indicated by reported clin-
ical cases of codeine-caused euphoria, dizziness, blurred vision
[185], severe deterioration of consciousness [186], apnea with
subsequent brain damage [187] up to fatal poisoning of breastfed
infants [188]. Tramadol metabolism by CYP2D6 also produces an
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Gene
SNP with reference ID 
(minor allele right)
† Gene position
Minor allele 
frequency (%)
Kind of pain or lumbar
disc disease (LDD)
Increased or
decreased pain or
LDD with minor allele
References
Genes associated with cartilage structure and stability
COL9A2
rs7533552C>T (c.976C>T;
Gln326Trp) ‘Trp2 allele’
Exon 19 1.9
Lumbar disc disease with
radicular pain
Increased [19]
rs12077871A>G (c.976A>G,
Gln326Arg)
Exon 19 25.5 Lumbar disc disease Increased [19, 20]
Haplotype from 3 COL9A2 
variants
21 Lumbar disc disease Increased [21]
COL9A3
ENSSNP1927949C>T,
Arg103Trp, ‘Trp3 allele’
Exon 5
12.2/4.7 
Case/control 
Lumbar disc disease  Increased [10]
COL11A1 rs1676486C>T Exon 62
35/26 
Case/control
Lumbar disc herniation Increased [23]
rs2229783 C>T Exon 63
41/32 
Case/control
Lumbar disc herniation Increased [23]
rs3753841T>C Exon 52
37/28 
Case/control
Lumbar disc herniation Increased [23]
COL11A2 rs1799907T>A
Intron 6 splice
site IVS6
( 4)T>A 
7/28 
Case/control
Lumbar disc disease with
stenosis and radicular
pain
Decreased A allele 
protective
[22]
COL1A1 rs1107946G>T  5 UTR 18
Lumbar disc disease,
osteoporosis
Increased [24, 29, 30]
VDR
rs10735810C>T additional tran-
scription start site, additional
three amino acids
Exon 2 ~30
Lumbar disc disease,
osteoporosis
Increased [37, 51, 52]
rs731236T>C Exon 9 ~25 Lumbar disc disease Increased [53]
ACAN
Variable number of tandem
repeats (VNTR) 
Exon 12 ~7 Lumbar disc disease
Increased with short
VNTRs
[43, 44]
LDD associated with 18–22 TRs,
protective effect of >25 TRs
CILP rs2073711T>4C  Exon 8
24.6/16.9
Case/control
Lumbar disc disease Increased [45]
MMP3 rs3025058 6A>5A ins/del 5 UTR ~20 (5A) Lumbar disc disease Increased [47, 48]
MMP9 rs17576A>G Exon 6 Lumbar disc herniation Increased [50]
THBS2 rs9406328C>T Intron 10 Lumbar disc herniation Increased [50]
Genes associated with inflammation
IL1RN rs2234677G>A Intron 8 26
Lumbar disc disease, Low
back pain
Increased [4]
IL1A rs1800587C>T 5 UTR 38.2
Lumbar disc disease, Low
back pain
Increased [57]
IL1B rs1143634C>T Intron 1 31
Lumbar disc disease, Low
back pain
Increased [4]
IL6 rs2069860T>A Exon 5 1.2
Lumbar disc disease,
radicular pain
Increased [62]
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Gene
SNP with reference ID 
(minor allele right)
† Gene position
Minor allele 
frequency (%)
Kind of pain or lumbar
disc disease (LDD)
Increased or
decreased pain or
LDD with minor allele
References
IL6 rs2069826 -597*G>A Promoter 45
Lumbar disc disease,
radicular pain
Increased [62]
rs3087226 -174*G>C Promoter 45
Lumbar disc disease,
radicular pain
Increased [62]
Genes associated with pain signalling
GCH1 rs8007267G>A 5 UTR 17
Chronic low back pain with
radicular pain; heat,
ischemic and pressure pain
Decreased
rs3783641A>T Intron 1 19 Decreased
rs8007201T>C Intron 3 28 Decreased
rs4411417A>G Intron 3 19 Decreased
rs752688G>A Intron 5 19 Decreased
Haplotype from 15 GCH1 SNPs 15.4
Chronic low back pain with
radicular pain; heat,
ischemic and pressure pain, 
Decreased
14.7 Inflammatory hyperalgesia Decreased [71]
COMT rs4646312T>C Promoter 33 Cold pain intensity Decreased [90]
rs6269A>G Intron 1 44 Cold pain intensity
Decreased or
increased
rs4633T>C Exon 3 49
Pressure pain, thermal
pain
Decreased [76]
rs4680 G>A Exon 4 -
Muscle pain due to
hypertonic saline
Increased [84]
rs4680 G>A Exon 4 -
Muscle pain due to
hypertonic saline
Increased [84]
Heat pain temporal sum-
mation
Increased [75, 199]
rs6269G/rs4633C/rs4818G/
rs4680G
36.5
Pressure pain, thermal
pain
Low [76]
rs6269A/rs4633T/rs4818C/
rs4680A
48.7 Average
rs6269A/rs4633C/rs4818C/
rs4680G
10.7 High
Haplotypes from 6 COMT SNPs -  Cold pain intensity Changed [90]
MC1R
rs1805007C>T,rs1805008C>T,
rs1805009G>C and other)
E.g. exon 1  ~2 Electrical pain tolerance Decreased [87]
TRPV1 rs8065080A>G Exon 12 36.8 Cold pain withdrawal time  Decreased [118]
TRPA1 rs11988795G>A Intron 20 41 Cold pain withdrawal time Increased [90]
Haplotypes from
rs13255063T>A and
rs11988795G>A 
-
Cold pain withdrawal
time, heat pain intensity
Changed
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Summary
Several genetic factors contribute to the risk for chronic back pain
and widespread pain syndromes (Table 1). The experience of pain
results from a complex interaction between several genetic variants
involved in different steps of neuronal processing of nociceptive
information with additional contribution of other genetic, struc-
tural, environmental and psychosocial factors. The investigation of
interactions between genetic variants that modify pain signalling
and the variants affecting bone and intervertebral cartilage and the
identification of the molecular consequences of functional variants
are further required to understand the genetics of pain and spe-
cially to identify genetic predictors of chronic back pain.
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References
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  Exon 1 10.9 Heat pain intensity 
Decreased or
unchanged
[118]
rs2234918T>C
  Exon 3 35.6 Heat pain intensity  Increased
FAAH rs932816G>A 5 UTR 19 Cold pain intensity Increased [90]
rs4141964T>C Intron 1 49 Cold pain intensity Increased [90]
Cold pain withdrawal time Increased
rs2295633G>A Intron 8 43 Cold pain intensity Increased [90]
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